The annual International Symposium on Hepatitis C Virus, Flaviviruses and Related Viruses is recognised internationally as the premier meeting for researchers working in the HCV and related flavivirus fields. Rotating through meeting venues in Europe, North America and Asia/Australia since 1992, the meeting has played a key role in both promoting excellence in research, driving discoveries in virus replication, pathogenesis and genetics, and providing the knowledge base for the spectacular advances in antiviral and vaccine development.

While HCV was originally the main focus of the symposium, its scope has recently been extended to other flaviviruses such as dengue, yellow fever, West Nile and Zika viruses, pestiviruses, pegiviruses and related viruses. Their incorporation into the meeting programme reflects the huge scientific, public health and vaccine development effort in the wider virus family, and the valuable context and knowledge this brings to the HCV field – and conversely, the extraordinary virological and therapeutic progress on HCV that may cross-fertilise flavivirus research.

This event will bring together leading experts, researchers, and healthcare professionals from around the world to discuss the latest advancements and research in the field of hepatitis C virus, flaviviruses, pestiviruses and related viruses. The program will deliver internationally renowned keynotes and plenary speakers, oral presentations selected from abstracts, rapid fire talks, and poster sessions.

Keynote Speaker

Dan Barouch, Harvard University

Prof. Dan Barouch received his Ph.D. in immunology from Oxford University and his M.D. from Harvard Medical School. He is currently the William Bosworth Castle Professor of Medicine at Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center, and a member of the Ragon Institute of MGH, MIT, and Harvard.

His laboratory focuses on studying the immunology and pathogenesis of viral infections and developing novel vaccine and treatment strategies. His group has led the development of vaccine candidates for HIV-1, Zika, SARS-CoV-2, tuberculosis, and influenza. His work contributed to the development of the Johnson & Johnson COVID-19 vaccine and the evaluation of multiple COVID-19 vaccines and therapeutics. He was elected to the American Society for Clinical Investigation (2009), Association of American Physicians (2013), and National Academy of Medicine (2020), and he received the King Faisal Prize in Medicine (2023).

Plenary Speakers